A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PLB1004.
- Who it may be relevant to
- Registry conditions: Non-Small Cell Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase I Open-label, Multi-dose, Dose Escalation and Dose Expansion Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Overview
This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dose escalation phase will include patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations, or uncommon mutations. Part 2 includes an expansion phase and the expansion phase will explore one or more dose levels of PLB1004 in NSCLC patients with EGFR Ex20ins mutations, classical mutations, or uncommon mutations.
Interventions
- Drug PLB1004
PLB1004 will be orally self-administered by the patient as a mono-therapy.
Primary outcome measures
- Safety profile of PLB1004 per CTCAE v5.0 [Time frame: Up to 2 years]
Secondary outcome measures (10)
- To define the DLTs and MTD [Time frame: Up to 3 years]
- Area Under the Curve (AUC) of PLB1004 [Time frame: Approximately 28 days.]
- Maximum plasma concentration (Cmax) of PLB1004 [Time frame: Approximately 28 days.]
- Time to maximum plasma concentration (Tmax) of PLB1004 [Time frame: Approximately 28 days.]
- Overall Response Rate (ORR) [Time frame: Up to 3 years]
- Progression-Free Survival (PFS) [Time frame: Up to 3 years]
- Overall Survival (OS) [Time frame: Up to 3 years]
- Disease Control Rate (DCR) [Time frame: Up to 3 years]
- Duration of Response (DOR) [Time frame: Up to 3 years]
- Change from baseline in corrected QT interval (QTc) using Fridericia formula (QTcF) [Time frame: Up to 3 years]
Eligibility criteria
Inclusion criteria
- Ability to understand and willingness to sign a written informed consent document;
- Male or female adult patients 18 years of age or older;
- Patients should have recovered from toxicities related to prior anti-tumor therapy;
- Patients should have recovered from the effects of major surgery;
- Have a documented EGFR mutation by a local test in tissue or plasma;
- At least 12 weeks life expectancy;
- Must have at least one measurable lesion per RECIST v 1.1;
- Sexually active males and females of childbearing potential must agree to take effective contraceptive measures.
Exclusion criteria
- Received radiotherapy within 14 days before enrollment;
- Have significant or uncontrolled systemic disease;
- Have significant or uncontrolled cardiovascular disease;
- Have had other diagnosed malignant diseases that required treatment within the past 3 years besides NSCLC;
- Currently have or had a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia that requires steroid therapy;
- Have known hypersensitivity to the similar drugs and excipients of PLB1004;
- Pregnant or lactating women;
- Have used other experimental drugs within 2 weeks prior to the first dose of PLB1004;
- Have any condition or illness that could affect the compliance with the protocol.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Sequential
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 7 centers
- University of California-Davis — Sacramento
- Research Site — Louisville
- Nebraska Cancer Specialists — Omaha
- Research Site — New York
- Sarah Cannon Research Institute — Nashville
- Swedish Health Sciences — Seattle
- Research Site — Seattle
Identifiers
NCT: NCT06046495 · PLB1004-I-US01